QPPV.COM KNOWLEDGE ASSESSMENT

Bupropion: Discovery, Development, Safety and Pharmacovigilance โ€” Professional Knowledge Assessment

Test your understanding of the concepts covered by Bupropion: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A seizure is reported in a patient taking two differently branded bupropion-containing products. What is the highest-priority exposure question?
Question 2 of 10 A suspected aseptic-meningitis report follows bupropion initiation. Which action best reflects sound pharmacovigilance practice?
Question 3 of 10 Which description best characterises the 1986 response to seizure reports in patients with bulimia?
Question 4 of 10 A patient taking bupropion starts a CYP2B6 inhibitor. Which interpretation is most appropriate?
Question 5 of 10 Which statement correctly interprets the seizure incidence figures cited for different bupropion formulations?
Question 6 of 10 A urine immunoassay is positive for amphetamines in a patient taking bupropion. What is the appropriate interpretation?
Question 7 of 10 In the smoking-cessation trial, the higher observed abstinence proportion with bupropion plus nicotine patch supports which conclusion?
Question 8 of 10 What is the key pharmacovigilance implication of the different IR, SR and XL release systems?
Question 9 of 10 A patient with a history of anorexia nervosa is being considered for a bupropion product. What is the most appropriate professional interpretation?
Question 10 of 10 A serious suspected adverse reaction is reported, but causality remains uncertain. What is the most appropriate operational response?

Select an answer to continue.

QPPV.com